866-997-4948(US-Canada Toll Free)

Chondrosarcoma - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 148 Pages

Chondrosarcoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chondrosarcoma Pipeline Review, H2 2016, provides an overview of the Chondrosarcoma (Oncology) pipeline landscape.

Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, changes in urination. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chondrosarcoma Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chondrosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chondrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.Chondrosarcoma.

Chondrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chondrosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chondrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chondrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chondrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chondrosarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chondrosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chondrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chondrosarcoma Overview 7
Therapeutics Development 8
Pipeline Products for Chondrosarcoma - Overview 8
Pipeline Products for Chondrosarcoma - Comparative Analysis 9
Chondrosarcoma - Therapeutics under Development by Companies 10
Chondrosarcoma - Therapeutics under Investigation by Universities/Institutes 11
Chondrosarcoma - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Chondrosarcoma - Products under Development by Companies 14
Chondrosarcoma - Products under Investigation by Universities/Institutes 15
Chondrosarcoma - Companies Involved in Therapeutics Development 16
Agios Pharmaceuticals, Inc. 16
Celgene Corporation 17
CytRx Corporation 18
EpiZyme, Inc. 19
Horizon Pharma Plc 20
Karyopharm Therapeutics, Inc. 21
Merck & Co., Inc. 22
Novartis AG 23
Pfizer Inc. 24
Chondrosarcoma - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
AG-120 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
aldoxorubicin hydrochloride - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
axitinib - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
enasidenib mesylate - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
interferon gamma-1b - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
pazopanib hydrochloride - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
pembrolizumab - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Peptide to Inhibit c-Myc and mTOR for Chondrosarcoma and Oncology - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
selinexor - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
sirolimus - Drug Profile 136
Product Description 136
Mechanism Of Action 136
R&D Progress 136
tazemetostat - Drug Profile 137
Product Description 137
Mechanism Of Action 137
R&D Progress 137
Chondrosarcoma - Dormant Projects 145
Chondrosarcoma - Discontinued Products 146
Appendix 147
Methodology 147
Coverage 147
Secondary Research 147
Primary Research 147
Expert Panel Validation 147
Contact Us 147
Disclaimer 148

List of Tables
Number of Products under Development for Chondrosarcoma, H2 2016 8
Number of Products under Development for Chondrosarcoma - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Chondrosarcoma - Pipeline by Agios Pharmaceuticals, Inc., H2 2016 16
Chondrosarcoma - Pipeline by Celgene Corporation, H2 2016 17
Chondrosarcoma - Pipeline by CytRx Corporation, H2 2016 18
Chondrosarcoma - Pipeline by EpiZyme, Inc., H2 2016 19
Chondrosarcoma - Pipeline by Horizon Pharma Plc, H2 2016 20
Chondrosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 21
Chondrosarcoma - Pipeline by Merck & Co., Inc., H2 2016 22
Chondrosarcoma - Pipeline by Novartis AG, H2 2016 23
Chondrosarcoma - Pipeline by Pfizer Inc., H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Chondrosarcoma - Dormant Projects, H2 2016 145
Chondrosarcoma - Discontinued Products, H2 2016 146

List of Figures
Number of Products under Development for Chondrosarcoma, H2 2016 8
Number of Products under Development for Chondrosarcoma - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Top 10 Targets, H2 2016 26
Number of Products by Stage and Top 10 Targets, H2 2016 26
Number of Products by Top 10 Mechanism of Actions, H2 2016 28
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28
Number of Products by Routes of Administration, H2 2016 30
Number of Products by Stage and Routes of Administration, H2 2016 30
Number of Products by Molecule Types, H2 2016 32
Number of Products by Stage and Molecule Types, H2 2016 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *